A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

被引：0

作者：

Stephen Couban

Giulia Benevolo

William Donnellan

Jennifer Cultrera

Steffen Koschmieder

Srdan Verstovsek

Gregory Hooper

Christian Hertig

Maneesh Tandon

Natalie Dimier

Vikram Malhi

Francesco Passamonti

机构：

[1] Queen Elizabeth II Health Sciences Centre,Department of Hematology, Oncology, Hemostaseology, and SCT, Faculty of Medicine

[2] Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino,Department of Leukemia

[3] Sarah Cannon Research Institute,undefined

[4] Florida Cancer Specialists,undefined

[5] Rheinisch-Westfälische Technische Hochschule Aachen University,undefined

[6] The University of Texas MD Anderson Cancer Center,undefined

[7] Roche Products Ltd,undefined

[8] Roche Clinical Science,undefined

[9] F. Hoffmann-La Roche Ltd.,undefined

[10] Genentech Research and Early Development,undefined

[11] Genentech,undefined

[12] Inc.,undefined

[13] Università degli Studi dell’Insubria,undefined

[14] Queen Elizabeth II Health Sciences Centre,undefined

来源：

Journal of Hematology & Oncology | / 11卷

关键词：

Vismodegib; Ruxolitinib; Myelofibrosis; Hedgehog pathway inhibitor; Hematopoiesis; Hematologic malignances;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
Couban, Stephen
Benevolo, Giulia
Donnellan, William
Cultrera, Jennifer
Koschmieder, Steffen
Verstovsek, Srdan
Hooper, Gregory
Hertig, Christian
Tandon, Maneesh
Dimier, Natalie
Malhi, Vikram
Passamonti, Francesco
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[2] Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis
Couban, Stephen
Benevolo, Giulia
Donnellan, William
Cultrera, Jennifer
Koschmieder, Steffen
Verstovsek, Srdan
Hooper, Gregory
Hertig, Christian
Tandon, Maneesh
Dimier, Natalie
Templeton, Ian
Passamonti, Francesco
BLOOD, 2017, 130
[3] FREEDOM: A phase 3b efficacy and safety study of fedrati nib in intermediate- or high-risk myelofibrosis patients previously treated with ruxolitinib.
Verstovsek, Srdan
Harrison, Claire N.
Barosi, Giovanni
Kiladjian, Jean-Jacques
Buglio, Daniela
Chia, Vincent
Gerike, Torsten
Jessent-Ciaravino, Valerie
Mostillo, Joseph
Zhang, Jun
Mesa, Ruben A.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[4] Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis
Kiladjian, Jean-Jacques
Heidel, Florian H.
Vannucchi, Alessandro M.
Ribrag, Vincent
Passamonti, Francesco
Hayat, Amjad
Conneally, Eibhlin
Martino, Bruno
Kindler, Thomas
Lipka, Daniel B.
Acharyya, Suddhasatta
Gopalakrishna, Prashanth
Ide, Susan E.
Loechner, Sabine
Mu, Song
Harrison, Claire N.
BLOOD, 2014, 124 (21)
[5] Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib
Gupta, Vikas
Yacoub, Abdulraheem
Fazal, Salman
Miller, Carole
Verstovsek, Srdan
Mesa, Ruben
Harrison, Claire
Barosi, Giovanni
Kiladjian, Jean-Jacques
Mattison, Ryan
Rein, Lindsay
Reeves, Brandi
Oh, Stephen
Parameswaran, Vinod
Deeg, Joachim
Rose, Shelonitda
Chia, Vincent
Wang, Tianhua
Talpaz, Moshe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S331 - S332
[6] Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Myelofibrosis
Gill, Harinder
Au, Lester
Leung, Garret Man Kit
Tsai, Dorothy
Yim, Rita
Chin, Lynn
Li, Vivian
Lee, Paul
Leung, Rock Yuk Yan
Lee, Elaine
Rienhoff, Hugh Young, Jr.
Kwong, Yok Lam
BLOOD, 2023, 142
[7] Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval
Srdan Verstovsek
Shreekant Parasuraman
Jingbo Yu
Anne Shah
Shambhavi Kumar
Ann Xi
Claire Harrison
Annals of Hematology, 2022, 101 : 131 - 137
[8] Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval
Verstovsek, Srdan
Parasuraman, Shreekant
Yu, Jingbo
Shah, Anne
Kumar, Shambhavi
Xi, Ann
Harrison, Claire
ANNALS OF HEMATOLOGY, 2022, 101 (01) : 131 - 137
[9] BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study
Lavie, David
Ribrag, Vincent
Loschi, Michael
Yannakou, Costas K.
Alwan, Maan
Abulafia, Adi Schacham
Hernandez-Rivas, Jesus Maria
Volchek, Yulia
Fong, Chun Yew
Bonifacio, Massimiliano
Kiladjian, Jean-Jacques
Ianotto, Jean-Christophe
Garcia Gutierrez, Valentin
Tucci, Alessandra
Xicoy, Blanca
Al-Ali, Haifa Kathrin
Talpaz, Moshe
Gerber, Jonathan M.
Raman, Indu
Tomuleasa, Ciprian
Lee-Hoeflich, Si Tuen
Das, Sharmila
Wu, Bin
Zhao, Qian
Kim, Eunhee
Esposito, Oriana
Liu, Yu
Nikolova, Zariana
Tehlirian, Christopher
Coker, Shodeinde
Ayala, Rosa
BLOOD, 2023, 142
[10] BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study
Ayala, Rosa
Lopez, Nieves
Abulafia, Adi Shacham
Alwan, Maan
Yannakou, Costas K.
Raman, Indu
Ribrag, Vincent
Fong, Chun Yew
Volchek, Yulia
Bonifacio, Massimiliano
Tucci, Alessandra
Kiladjian, Jean-Jacques
Chang, Henry
Das, Sharmila
Wu, Bin
Ravindran, Palanikumar
Shan, Vivian
Wang, Guan
Esposito, Oriana
Liu, Yu
Nikolova, Zariana
Tehlirian, Christopher
Coker, Shodeinde
Lavie, David
BLOOD, 2022, 140 : 9665 - 9667

← 1 2 3 4 5 →